Literature DB >> 15915537

Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets.

Nadia Caccamo1, Serena Meraviglia, Viviana Ferlazzo, Daniela Angelini, Giovanna Borsellino, Fabrizio Poccia, Luca Battistini, Francesco Dieli, Alfredo Salerno.   

Abstract

We have compared four human subsets of Vgamma9Vdelta2 T cells, naive (T(naive), CD45RA(+)CD27(+)), central memory (T(CM), CD45RA(-)CD27(+)), effector memory (T(EM), CD45RA(-)CD27(-)) and terminally differentiated (T(EMRA), CD45RA(+)CD27(-)), for their capacity to proliferate and differentiate in response to antigen or homeostatic cytokines. Cytokine responsiveness and IL-15R expression were low in T(naive) cells and progressively increased from T(CM) to T(EM) and T(EMRA) cells. In contrast, the capacity to expand in response to antigen or cytokine stimulation showed a reciprocal pattern and was associated with resistance to cell death and Bcl-2 expression. Whereas antigen-stimulated cells acquired a T(CM) or T(EM) phenotype, IL-15-stimulated cells maintained their phenotype, with the exception of T(CM) cells, which expressed CD27 and CD45RA in various combinations. These results, together with ex vivo bromodeoxyuridine incorporation experiments, show that human Vgamma9Vdelta2 memory T cells have different proliferation and differentiation potentials in vitro and in vivo and that T(EMRA) cells are generated from the T(CM) subset upon homeostatic proliferation in the absence of antigen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15915537     DOI: 10.1002/eji.200525983

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  42 in total

1.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes.

Authors:  Gabriele Pizzolato; Hannah Kaminski; Marie Tosolini; Don-Marc Franchini; Fréderic Pont; Fréderic Martins; Carine Valle; Delphine Labourdette; Sarah Cadot; Anne Quillet-Mary; Mary Poupot; Camille Laurent; Loic Ysebaert; Serena Meraviglia; Francesco Dieli; Pierre Merville; Pierre Milpied; Julie Déchanet-Merville; Jean-Jacques Fournié
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-22       Impact factor: 11.205

3.  Clonal expansion shapes the human Vδ1T cell receptor repertoire.

Authors:  Serena Meraviglia; Francesco Dieli
Journal:  Cell Mol Immunol       Date:  2017-07-24       Impact factor: 11.530

Review 4.  Understanding the complexity of γδ T-cell subsets in mouse and human.

Authors:  Dick J Pang; Joana F Neves; Nital Sumaria; Daniel J Pennington
Journal:  Immunology       Date:  2012-07       Impact factor: 7.397

5.  Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor.

Authors:  A Bertaina; A Zorzoli; A Petretto; G Barbarito; E Inglese; P Merli; C Lavarello; L P Brescia; B De Angelis; G Tripodi; L Moretta; F Locatelli; I Airoldi
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

Review 6.  Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.

Authors:  Diego Marquez-Medina; Joel Salla-Fortuny; Antonieta Salud-Salvia
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

7.  Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.

Authors:  Joshua M Lang; Mahazarin R Kaikobad; Marianne Wallace; Mary Jane Staab; Dorothea L Horvath; George Wilding; Glenn Liu; Jens C Eickhoff; Douglas G McNeel; Miroslav Malkovsky
Journal:  Cancer Immunol Immunother       Date:  2011-06-07       Impact factor: 6.968

8.  Characterization of γδ T Cell Effector/Memory Subsets Based on CD27 and CD45R Expression in Response to Mycobacterium bovis Infection.

Authors:  Mariana Guerra-Maupome; Mitchell V Palmer; W Ray Waters; Jodi L McGill
Journal:  Immunohorizons       Date:  2019-06-12

9.  Characteristics of γδ T cells in Schistosoma japonicum-infected mouse mesenteric lymph nodes.

Authors:  Xiuxue Yu; Xueping Luo; Hongyan Xie; Dianhui Chen; Lu Li; Fan Wu; Changyou Wu; Anping Peng; Jun Huang
Journal:  Parasitol Res       Date:  2014-07-05       Impact factor: 2.289

10.  Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma.

Authors:  Kia Joo Puan; John Seng Hooi Low; Terence Wee Kiat Tan; Joseph Tien Seng Wee; Eng Huat Tan; Kam Weng Fong; Eu Tiong Chua; Chenggang Jin; José-Luis Giner; Craig T Morita; Christopher Hood Keng Goh; Kam M Hui
Journal:  Cancer Immunol Immunother       Date:  2008-11-30       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.